Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IDRA
  • CUSIP: N/A
  • Web: www.iderapharma.com
Capitalization:
  • Market Cap: $353.13 million
  • Outstanding Shares: 149,631,000
Average Prices:
  • 50 Day Moving Avg: $2.27
  • 200 Day Moving Avg: $1.98
  • 52 Week Range: $1.30 - $2.87
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.72
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.17 million
  • Price / Sales: 21.84
  • Book Value: $0.50 per share
  • Price / Book: 4.72
Profitability:
  • EBITDA: ($42,730,000.00)
  • Net Margins: -300.63%
  • Return on Equity: -61.09%
  • Return on Assets: -55.14%
Debt:
  • Current Ratio: 11.08%
  • Quick Ratio: 11.08%
Misc:
  • Average Volume: 1.07 million shs.
  • Beta: 2.24
  • Short Ratio: 16.44
 

Frequently Asked Questions for Idera Pharmaceuticals (NASDAQ:IDRA)

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its earnings results on Monday, August, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 61.09%. View Idera Pharmaceuticals' Earnings History.

When will Idera Pharmaceuticals make its next earnings announcement?

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Idera Pharmaceuticals.

Where is Idera Pharmaceuticals' stock going? Where will Idera Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1-year target prices for Idera Pharmaceuticals' shares. Their predictions range from $4.00 to $8.00. On average, they expect Idera Pharmaceuticals' share price to reach $5.75 in the next year. View Analyst Ratings for Idera Pharmaceuticals.

What are analysts saying about Idera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (10/11/2017)
  • 2. Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a drop in short interest in the month of September. As of September 29th, there was short interest totalling 9,959,849 shares, a drop of 20.1% from the September 15th total of 12,467,728 shares. Based on an average daily volume of 925,047 shares, the days-to-cover ratio is presently 10.8 days. Currently, 7.8% of the company's shares are short sold.

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Independent Chairman of the Board
  • Vincent J. Milano, President, Chief Executive Officer, Director
  • Youssef El Zein, Independent Vice Chairman of the Board
  • Louis J. Arcudi III, Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
  • Robert Clayton Fletcher, Senior Vice President - Business Development and Strategic Planning
  • Joanna C. Horobin M.D., Senior Vice President, Chief Medical Officer
  • Robert A. Doody Jr., Vice President - Investor Relations and Corporate Communications
  • William S. Reardon CPA, Lead Independent Director
  • Maxine Gowen Ph.D., Director
  • Julian C. Baker, Independent Director

How do I buy Idera Pharmaceuticals stock?

Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of Idera Pharmaceuticals stock can currently be purchased for approximately $2.36.


MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.75 (143.64% upside)
Consensus Price Target History for Idera Pharmaceuticals (NASDAQ:IDRA)
Price Target History for Idera Pharmaceuticals (NASDAQ:IDRA)
Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00LowView Rating Details
4/24/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$5.00MediumView Rating Details
4/11/2017WedbushReiterated RatingOutperform$6.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$8.00HighView Rating Details
11/29/2016Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 -> $2.10N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)
Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Earnings History by Quarter for Idera Pharmaceuticals (NASDAQ IDRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017($0.12)N/AView Earnings Details
8/7/2017Q2 2017($0.11)($0.14)$0.20 million$0.19 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.10)($0.10)$0.20 million$0.38 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.11)$0.01$0.32 million$15.28 millionViewN/AView Earnings Details
10/28/2016Q3($0.11)($0.10)$0.30 million$0.32 millionViewN/AView Earnings Details
8/2/2016Q216($0.11)($0.11)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)$0.20 million$0.29 millionViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$0.03 million$0.19 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)$0.02 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)$0.01 millionViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)$0.03 millionViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)$0.04 millionViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)
2017 EPS Consensus Estimate: ($0.39)
2018 EPS Consensus Estimate: ($0.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.10)($0.10)($0.10)
Q4 20171($0.10)($0.10)($0.10)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Ownership Percentage: 30.29%
Institutional Ownership Percentage: 30.94%
Insider Trades by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Insider Trades by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Invest Corp PillarDirectorSell450,815$2.26$1,018,841.90View SEC Filing  
4/25/2017Invest Corp PillarDirectorSell1,328,422$2.29$3,042,086.38View SEC Filing  
4/24/2017Invest Corp PillarDirectorSell437,829$2.29$1,002,628.41View SEC Filing  
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.12View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.00View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Idera Pharmaceuticals (NASDAQ:IDRA)
Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)
Source:
DateHeadline
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 3:36 AM
finance.yahoo.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 7:33 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Sees Large Drop in Short Interest
www.americanbankingnews.com - October 13 at 1:32 AM
americanbankingnews.com logoIdera Pharmaceuticals (IDRA) & Prana Biotechnology (PRAN) Head-To-Head Contrast
www.americanbankingnews.com - October 11 at 6:22 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 8 at 2:56 AM
finance.yahoo.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 1:16 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Short Interest Update
www.americanbankingnews.com - September 28 at 3:18 AM
finance.yahoo.com logoIs It Time To Buy Idera Pharmaceuticals Inc (IDRA)?
finance.yahoo.com - September 20 at 9:08 PM
finance.yahoo.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 7:50 PM
finance.yahoo.com logoIdera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 7:15 PM
seekingalpha.com logoIdera Pharmaceuticals: This ESMO Winner Is A Buy - Seeking Alpha
seekingalpha.com - September 17 at 12:00 AM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Sees Significant Decline in Short Interest
www.americanbankingnews.com - September 15 at 1:02 AM
nasdaq.com logoIdera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4% - Nasdaq
www.nasdaq.com - September 14 at 11:45 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 3:14 AM
americanbankingnews.com logoIdera Pharmaceuticals' (IDRA) Buy Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - September 12 at 5:08 PM
streetinsider.com logoPre-Open Movers 09/11: (MRNS) (IDRA) (TEVA) Higher; (ACHN) (EGO) (USG) Lower (more...)
www.streetinsider.com - September 11 at 8:13 PM
seekingalpha.com logoIdera Pharmaceuticals (IDRA) Presents On IMO - 2125 Climical Data Update - Slideshow
seekingalpha.com - September 11 at 8:13 PM
finance.yahoo.com logoHere's Why Idera Pharmaceuticals, Inc. Is Surging Today
finance.yahoo.com - September 11 at 8:13 PM
fool.com logoHere's Why Idera Pharmaceuticals, Inc. Is Surging Today
www.fool.com - September 11 at 1:17 PM
finance.yahoo.com logoIdera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy
finance.yahoo.com - September 10 at 6:49 PM
streetinsider.com logoIdera Pharma (IDRA) Reports Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab - StreetInsider.com
www.streetinsider.com - September 9 at 7:08 PM
streetinsider.com logoIdera Pharma (IDRA) Reports Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab
www.streetinsider.com - September 8 at 8:54 PM
finance.yahoo.com logoIdera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory
finance.yahoo.com - September 8 at 8:54 PM
globenewswire.com logoIdera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 AMET - GlobeNewswire (press release)
globenewswire.com - September 8 at 1:03 AM
finance.yahoo.com logoIdera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.
finance.yahoo.com - September 6 at 7:41 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (IDRA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 19 at 2:42 AM
seekingalpha.com logoIdera Pharmaceuticals (IDRA) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 16 at 7:43 PM
globenewswire.com logoIdera to Present at the 2017 Wedbush PacGrow Healthcare ... - GlobeNewswire (press release)
globenewswire.com - August 12 at 1:15 AM
americanbankingnews.com logoWedbush Comments on Idera Pharmaceuticals, Inc.'s FY2017 Earnings (IDRA)
www.americanbankingnews.com - August 11 at 12:02 PM
feeds.benzinga.com logoIdera to Present at the 2017 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 11 at 11:34 AM
globenewswire.com logoIdera Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 8 at 7:27 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - August 8 at 3:48 PM
finance.yahoo.com logoIdera reports 2Q loss
finance.yahoo.com - August 8 at 12:14 AM
finance.yahoo.com logoIdera Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 7 at 7:13 PM
americanbankingnews.com logoIdera Pharmaceuticals, Inc. (NASDAQ:IDRA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 25 at 11:38 AM
americanbankingnews.com logoHead to Head Analysis: Idera Pharmaceuticals (IDRA) vs. Regulus Therapeutics (RGLS)
www.americanbankingnews.com - July 24 at 8:22 PM
finance.yahoo.com logoETFs with exposure to Idera Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 11:40 PM
prnewswire.com logoTechnical Insights on Biotech Stocks -- Idera Pharma, Pieris Pharma, Peregrine Pharma, and Ritter Pharma
www.prnewswire.com - July 5 at 8:15 AM
streetinsider.com logoIdera Pharma (IDRA) Granted FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma
www.streetinsider.com - June 23 at 6:10 PM
investorplace.com logo3 Stocks to Watch on Friday: Bed Bath & Beyond Inc. (BBBY), Sonic Corporation (SONC) and Idera Pharmaceuticals Inc (IDRA)
investorplace.com - June 23 at 8:34 AM
streetinsider.com logoIdera Pharma (IDRA) Granted FDA Orphan Drug Designation for ... - StreetInsider.com
www.streetinsider.com - June 23 at 1:21 AM
globenewswire.com logoIdera to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 5 at 10:56 PM
nasdaq.com logoIdera to Present at the Jefferies 2017 Healthcare Conference - Nasdaq
www.nasdaq.com - June 5 at 5:55 PM
fool.com logoHere's Why Idera Pharmaceuticals, Inc. Is Sinking Today - Motley Fool
www.fool.com - May 5 at 10:52 PM
marketbeat.com logoIdera reports 1Q loss
marketbeat.com - May 4 at 6:57 PM
streetinsider.com logoBaird Starts Idera Pharmaceuticals (IDRA) at Outperform - StreetInsider.com
www.streetinsider.com - April 26 at 7:29 PM
benzinga.com logoWith More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform - Benzinga
www.benzinga.com - April 26 at 7:29 PM
benzinga.com logoExclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate
www.benzinga.com - April 20 at 10:58 PM
globenewswire.com logoIdera Pharmaceuticals Announces Organizational Update - GlobeNewswire (press release)
globenewswire.com - April 19 at 5:43 PM
streetinsider.com logoIdera Pharma (IDRA) Advances Intratumoral IMO-2125 in Combination with Ipilimumab for Unmet Need in Anti-PD-1 ... - StreetInsider.com
www.streetinsider.com - April 12 at 5:58 PM

Social

Chart

Idera Pharmaceuticals (IDRA) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.